Premature ovarian failure and cardiovascular diseases


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The impact of estrogen deficiency in women with timely menopause on the risk of cardiovascular diseases (CVD) is now widely discussed. However, there are very few papers dealing with this problem in female patients with premature ovarian failure (POF). Objective. To summarize the data of current clinical trials of the problem of CVD development in women with POF. Subject and methods. Good-quality bibliographic references published in the PubMed database on the studies of surrogate markers and endpoints for the development of CVD in women with POF were reviewed. Results. Analysis of the performed investigations has shown that POF-induced estrogen deficiency is a significant and traditional CVD risk-independent predictor of coronary heart disease and strokes, the relative risk of which in this pathology is 2.11 and 2.10, respectively. Conclusion. To confirm the significant role of POF-induced estrogen deficiency in the development of CVD, it is necessary to conduct large-scale randomized controlled trials, by not only thoroughly analyzing the predictors of CVD, but also by necessarily accounting cardiovascular events in this category of patients.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Anna Pozdnyakova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: anna_pozd@mail.ru
graduate student of 3rd year of training

Larisa Marchenko

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: l.a.marchenko@yandex.ru
doctor of medical sciences, professor, leading researcher of Department of Gynecological Endocrinology

Nadezhda Runikhina

National Research Center for Preventive Medicine

Email: runishi@rambler.ru
MD, Professor, Head of the Geriatric Laboratory

Nataliya Sharashkina

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: sharashkina@inbox.ru
Candidate of Medical Sciences, therapist, Department of Therapeutics

Әдебиет тізімі

  1. Дзяк Л.А., Цуркаленко Е.С. Инсульт у пациентов молодого возраста. Практическая ангиология. 2010; 2/1(Спецвыпуск): 5-10. [Dzyak L.A., Tsurkalenko E.S. Stroke in young patients. Prakticheskaya angiologiya. 2010; 2/1(Special Issue): 5-10. (in Russian)]
  2. Mosca L., Banka C.L., Benjamin E.J., Berra K., Bushnell C., Dolor R.J. et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007; 115(11): 1481-501.
  3. Габибуллаева З.Г. Клинико-генетическая характеристика больных с преждевременной недостаточностью яичников: дисс.. канд. мед. наук. М.; 2008.163c. [Gabibullaeva Z.G. Clinical and genetic characteristics of patients with premature ovarian failure. Diss. Moscow; 2008.163 p. (in Russian)]
  4. Инжутова А.И. Клеточно-гуморальные характеристики патологического процесса осложненных форм гипертонической болезни. Сибирский медицинский журнал (Томск). 2006; 21(1, приложение): 46-7. [Inzhutova A.I. Cellular humoral pathological characteristics of complicated forms of hypertension. Siberian Medical Journal (Tomsk). 2006; 21 (1 application): 46-7. (in Russian)]
  5. van Oostrom A.J., Sijmonsma T.P., Verseyden C., Jansen E.H., de Koning E.J., Rabelink T.J. et al. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J. Lipid Res. 2003; 44(3): 576-83.
  6. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993; 269(23): 3015
  7. Grundy S, Cleeman J, Merz C, Brewer H.B.Jr., Clark L.T., Hunninghake D.B. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. 2004; 44(3): 720-32.
  8. de Villiers T.J., Pines A., Panay N., Gambacciani M., Archer D. F., Baber R. J. et al.; International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013; 16(3): 316-37.
  9. de Villiers T.J., Gass M.L.S., Haines C.J., Hall J.E., Lobo R.A., Pierroz D.D., Rees M. Global Consensus Statement on menopausal hormone therapy. Maturitas. 2013; 74(4): 391-2.
  10. Aird W.C., ed. Endothelial cells in health and disease. Informa HealthCare; 2005. 512p.
  11. Esper R.J., Nordaby R.A., Vilarino J.O., Paragano A., Cacharrön J.L., Machado R.A. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc. Diabetol. 2006; 5: 4-10.
  12. Инжутова А.И., Салмина А.Б., Петрова М.М., Михуткина С.В., Народова В.В., Домрачев Д.В. Регистрация блеббинга плазматической мембраны лимфоцитов периферической крови как экспресс-метод оценки тяжести состояния больных осложненными формами гипертонической болезни. Бюллетень СО РАМН. 2007; 1: 6-10. [Inzhutova A.I., Salmina A.B., Petrova M.M., Mikhutkina S.V., Narodova V.V., Domrachev D.V. Register of blebbing of the plasma membrane of peripheral blood lymphocytes as a rapid method for assessing the severity of patients with complicated forms of hypertension. Bulletin SB RAMS. 2007; 1: 6-10. (in Russian)]
  13. Парахонский А.П. Иммунная система как предиктор эндотелиальной дисфункции при артериальной гипертонии с метаболическими нарушениями. Фундаментальные исследования. 2007; 9: 74-5. [Parahonskiy A.P. The immune system as a predictor of endothelial dysfunction in patients with arterial hypertension and metabolic disorders. Fundamentalnyie issledovaniya. 2007; 9: 74-5. (in Russian)]
  14. Aird W.C., ed. Endothelial biomedicine. Cambridge: University Press; 2007. 1500p.
  15. Baker L., Meldrum K.K., Wang M., Sankula R., Vanam R., Raiesdana A. et al. The role of estrogen in cardiovasculare disease. J. Surg. Res. 2003; 115(2): 325-44.
  16. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 1999; 340(23): 1801-11.
  17. Вельков В.В. С-реактивный белок и липопротеин-ассоциированная фосфолипаза А2: новые факты и новые возможности для диагностики и стратификации сердечно-сосудистых рисков СРБ: в интерфазе между врожденным иммунитетом и воспалением. Поликлиника. 2010; 1: 18-21. [Velkov V.V. C-reactive protein and lipoprotein-associated phospholipase A2, new facts and new possibilities for the diagnosis and stratification of cardiovascular risk CRP: at the interface between innate immunity and inflammation. Poliklinika. 2010; 1: 18-21. (in Russian)]
  18. Rahman I., Akesson A., Wolk A. Relationship between age at natural menopause and risk of heart failure. Menopause. 2015; 22(1): 12-6.
  19. Bretherick K., Fluker M.R., Robinson WP FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum. Genet. 2005; 117(4): 376-8.
  20. Longo V.D., Mitteldorf J., Skulachev V.P. Programmed and altruistic ageing. Nat. Rev. Genet. 2005; 6(11): 866-72.
  21. Luoma P., Melberg A., Rinne J.O., Kaukonen J.A., Nupponen N.N., Chalmers R.M. et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet. 2004; 364(9437): 875-82.
  22. Wellons M., Ouyang P., Schreiner P.J., Herrington D.M., Vaidya D. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis (MESA). Menopause. 2012; 19(10): 1081-7.
  23. Stuenkel C.A. Cardiovascular risk and early menopause: cause or consequence? Menopause. 2012; 19(10): 1067-9.
  24. Hu F.B., Grodstein F., Hennekens C.H., Colditz G.A., Johnson M., Manson J.E. et al. Age at natural menopause and risk of cardiovascular disease. Arch. Intern. Med. 1999; 159(10): 1061-6.
  25. Jacobsen B., Nilssen S., Heuch I., Kvale G. Does age at natural menopause affect mortality from ischemic heart disease? J. Clin. Epidemiol. 1997; 50(4): 475-9.
  26. Jacobsen B., Knutsen S., Fraser G. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J. Clin. Epidemiol. 1999; 52(4): 303-7.
  27. van der Schouw Y., van der Graaf Y., Steyerberg E., Eijkemans J., Banga J. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996; 347(9003): 714-8.
  28. Knauff E.A., Westerveld H.E., Goverde A.J., Eijkemans M.J., Valkenburg O., van Santbrink E.J. et al. Lipid profile of women with premature ovarian failure. Menopause. 2008; 15(5): 919-23.
  29. Gulhan I., Bozkaya G., Uyar I., Oztekin D., Pamuk B.O., Dogan E. Serum lipid levels in women with premature ovarian failure. Menopause. 2012; 19(9): 1231-4.
  30. Verit F.F., Keskin S., Omer B., Yalcinkaya S., Sakar N. Is there any relationship between cardiovascular risk markers and young women with diminished ovarian reserve? Gynecol. Endocrinol. 2014; 30(10): 697-700.
  31. Kalantaridou S.N., Naka K.K., Papanikolaou E., Kazakos N., Kravariti M., Calis K.A. et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J. Clin. Endocrinol. Metab. 2004; 89(8): 3907-13.
  32. Cui R., Iso H., Toyoshima H., Date C., Yamamoto A., Kikuchi S. et al. Relationships of age at menarche and menopause, and reproductive year with mortality from cardiovascular disease in Japanese postmenopausal women: the JACC study. J. Epidemiol. 2006; 16(5): 177-84.
  33. Alonso de Lecinana M., Egido J.A., Fernândez C., Martinez-Vila E., Santos S., Morales A. et al. Risk of ischemic stroke and lifetime estrogen exposure. Neurology. 2007; 68(1): 33-8.
  34. Lisabeth L.D., Beiser A.S., Brown D.L., Murabito J.M., Kelly-Hayes M., Wolf P.A. Age at natural menopause and risk of ischemic stroke: The Framingham heart study. Stroke. 2009; 40(4): 1044-9.
  35. Baba Y., Ishikawa S., Amagi Y., Kayaba K., Gotoh T., Kajii E. Premature menopause is associated with increased risk of cerebral infarction in Japanese women. Menopause. 2010; 17(3): 506-10.
  36. Rivera C.M., Grossardt B.R., Rhodes D.J., Brown R.D. Jr., Roger V.L., Melton L.J. 3rd, Rocca W.A. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009; 16(1): 15-23.
  37. Parker W.H., Broder M.S., Chang E., Feskanich D., Farquhar C., Liu Z. et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses’ health study. Obstet. Gynecol. 2009; 113(5): 1027-37.
  38. Shuster L.T., Grossardt B.R., Gostout B.S., Rocca W.A. Prophylactic bilateral oophorectomy jeopardizes long-term health. Sex. Reprod. Menopause. 2010; 8(Suppl.1): S3-5.
  39. Shuster L.T., Rhodes D.J., Gostout B.S., Grossardt B.R., Rocca W.A. Premature menopause or early menopause: long-term health consequences. Maturitas. 2010; 65(2): 161-6.
  40. De Vos M., Devroey P., Fauser B.C. Primary ovarian insufficiency. Lancet. 2010; 376(9744): 911-21.
  41. Vujovic S., Brincat M., Erel T., Gambacciani M., Lambrinoudaki I., Moen M.H. et al. EMAS position statement: Managing women with premature ovarian failure. Maturitas. 2010; 67(1): 91-3.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2015

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>